Quick Answer
Tango Therapeutics, Inc. reported Cash And Cash Equivalents At Carrying Value of $112.28 million for the year ending 2025.
- Tango Therapeutics, Inc. showed an increase of +61.5% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
- This data is from Tango Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 5, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2020: $25.0 thousand | Q3 2020: $1.55 million | Q1 2021: $1.26 million | Q2 2021: $582.9 thousand | Q3 2021: $204.97 million | Q1 2022: $99.91 million | Q2 2022: $104.58 million | Q3 2022: $100.31 million | Q1 2023: $57.25 million | Q2 2023: $66.05 million | Q3 2023: $58.53 million | Q1 2024: $61.16 million | Q2 2024: $51.57 million | Q3 2024: $53.15 million | Q1 2025: $58.43 million | Q2 2025: $39.27 million | Q3 2025: $58.34 million.
- Over the full 6 years of available data (2020 to 2025), Tango Therapeutics, Inc.'s Cash And Cash Equivalents At Carrying Value has grown by 295.6%.
- Historical annual values: Fiscal year 2025: $112.28 million | Fiscal year 2024: $69.53 million | Fiscal year 2023: $66.39 million | Fiscal year 2022: $59.97 million | Fiscal year 2021: $142.75 million | Fiscal year 2020: $28.38 million.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: